Literature DB >> 11016749

Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity.

J J Michels1, F Duigou, J Marnay.   

Abstract

From 1990 to 1996, 607 previously untreated, node-negative, invasive breast carcinomas were sampled by a pathologist for flow-cytometric DNA analysis. The aim of the present work was to study the correlations between flow cytometric results obtained thanks to the American Consensus (AC) guidelines of 1993 and the established clinico-pathological prognostic factors (T, grade, receptors), and despite a short global follow-up (mean of 4 years), to correlate flow cytometry with the outcome of the patients. In this study S-phase fraction (SPF) correlated strongly with tumor size, histological grade, lack of steroid receptors, histological type and was together with the mitotic activity a paramount prognostic factor even after multivariate analysis. This study compared also the technical criteria proposed by the AC with our own more stringent ones and concluded that the criteria of the AC are relevant and allow, thanks to the use of tertiles in the reporting of SPF values, a comparison of values obtained by different teams. Our review of the literature, focused on series using fresh material, enabled us to show that there is a rather wide agreement concerning the relationship between SPF and prognosis most often after multivariate analysis. This despite the lack of standardization in the design of the studies (implementation of the technical steps or reporting of results). When estimated from fresh or frozen material following AC's guidelines. SPF along with mitotic activity should become a prognostic factor used in the daily practice by oncologists in the management of breast carcinomas.

Entities:  

Mesh:

Year:  2000        PMID: 11016749     DOI: 10.1023/a:1006451908322

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.

Authors:  K Jirström; L Rydén; L Anagnostaki; B Nordenskjöld; O Stål; S Thorstenson; G Chebil; P-E Jönsson; M Fernö; G Landberg
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

2.  Prognostic relevance of DNA flow cytometry in breast cancer revisited: The 25-year experience of the Portuguese Institute of Oncology of Lisbon.

Authors:  António E Pinto; Teresa Pereira; Giovani L Silva; Saudade André
Journal:  Oncol Lett       Date:  2017-02-13       Impact factor: 2.967

3.  High-throughput fluorescence-activated nanoscale subcellular sorter with single-molecule sensitivity.

Authors:  Perry G Schiro; Jennifer C Gadd; Gloria S Yen; Daniel T Chiu
Journal:  J Phys Chem B       Date:  2012-05-29       Impact factor: 2.991

4.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

5.  Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in libya.

Authors:  Eramah Ermiah; Abdelbaset Buhmeida; Fathi Abdalla; Ben Romdhane Khaled; Nada Salem; Seppo Pyrhönen; Yrjö Collan
Journal:  J Cancer       Date:  2012-10-01       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.